JP2006306804A - Wrinkle formation inhibitor - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a material inhibiting wrinkle formation, and a cosmetic agent or a food and drink composition for inhibiting wrinkle formation comprising the same. <P>SOLUTION: The wrinkle formation inhibitor contains acteoside of the formula as an active ingredient. The wrinkle formation inhibitor is compounded with the cosmetic agent and the food and drink composition for inhibiting wrinkle formation. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a wrinkle formation inhibitor comprising acteoside as an active ingredient.

  Since the skin is the outermost layer of the living body, it is directly affected by the environment such as exposure to ultraviolet rays, and various troubles occur. Among them, wrinkles are formed by aging due to aging and aging due to ultraviolet rays (photoaging), which is a major cosmetic problem. In particular, wrinkles formed by ultraviolet rays are prominent and prominent, and it is considered that chronic production of reactive oxygen species and a decrease in SOD activity are involved in the formation thereof.

Thus, in order to suppress the formation of wrinkles, the use of antioxidants (Patent Document 1), plant extracts (Patent Document 2), retinoic acid δ-tocopheryl (Patent Document 3), etc. has been proposed so far. ing. On the other hand, use of isoflavone glycosides (Patent Document 4) and coenzyme Q ₁₀ (Non-Patent Document 1) has been reported as oral foods. However, these wrinkle formation suppressing effects are not always satisfactory, and a more effective wrinkle formation suppressing material has been demanded.

  On the other hand, acteoside is a compound widely contained in plants, and has been reported to have an antioxidant effect (Non-patent Document 2). And various functions and physiology as an ultraviolet absorber (patent document 5), 5-lipoxygenase inhibitor (patent document 6), allergy and adult disease prevention food (patent document 7), fading inhibitor (patent document 8), etc. Activity has been found.

Japanese Patent Laid-Open No. 62-19511 JP-A-8-175955 JP 2004-339101 A JP 2005-29481 A JP-A-8-119842 JP-A-8-59685 JP 61-291525 A Japanese Patent Laid-Open No. 2002-173608 Food Style 21, Vol.8, No.6, p52-54, 2004 J. Agric. Food Chem., Vol.49, p3113-3119, 2001

Under such circumstances, the object of the present invention is to effectively suppress wrinkles formed by external factors such as ultraviolet rays and internal factors such as aging by means of external application and / or internal use. It is in providing the wrinkle formation inhibitor which can do.

As a result of intensive studies in view of the above circumstances, the present inventors have confirmed that wrinkle formation due to ultraviolet irradiation is suppressed by external application and / or oral intake of acteoside, thereby completing the present invention. It came to. That is, this invention exists in the wrinkle formation inhibitor characterized by containing the acteoside represented by the following Formula as an active ingredient.

  The second invention of the present application is that the wrinkle formation inhibitor is a vegetation water obtained by squeezing olive fruit, or a solid phase part and / or an aqueous phase part obtained by squeezing olive fruit. According to a third aspect of the present invention, there is provided a wrinkle formation inhibitor, wherein the wrinkle formation inhibitor contains water and / or an organic solvent from a solid phase part and / or an aqueous phase part obtained by pressing olive fruit. A wrinkle formation inhibitor characterized by being an extract obtained by use and extraction. According to a fourth aspect of the present invention, there is provided the aforementioned wrinkle formation inhibitor, wherein the content of acteoside in the wrinkle formation inhibitor is 1.0% by mass or more.

  The fifth invention of the present application is a cosmetic comprising the above-mentioned wrinkle formation inhibitor, and the amount of acteoside as an active ingredient of the wrinkle formation inhibitor is 0 based on the total amount of the cosmetic. It is in the cosmetic for wrinkle formation suppression characterized by being 0.001-2.0 mass%. The sixth invention of the present application is a food / beverage product composition containing the wrinkle formation inhibitor, and the amount of acteoside, which is an active ingredient of the wrinkle formation inhibitor, is the total amount of the food / beverage product composition. The wrinkle formation-inhibiting food / beverage composition, which is 0.001 to 10.0% by mass based on Further, the seventh invention of the present application lies in an ingestion method characterized in that 0.001 to 0.05 g of acteoside, which is an active ingredient of the wrinkle formation inhibitor, is orally administered per day.

  The wrinkle formation inhibitor of the present invention is characterized by containing acteoside as an active ingredient, and can suppress the formation of wrinkles that occur due to photoaging due to ultraviolet exposure and natural aging due to aging.

  Acteoside, which is an active ingredient of the wrinkle formation inhibitor of the present invention, is known to be contained in various plants such as oleaceae, perillaceae, saccharidaceae, lobster, pepper, etc. It is not limited. The acteoside used in the present invention can be obtained, for example, by selecting an appropriate one from the plant and extracting and purifying it. Moreover, you may use a general commercial item. Olea europaea L. fruit is preferably used because it is relatively easy to obtain as a raw material and the yield of acteoside is good. As a fruit, it can be used regardless of origin, variety, food, and oil extraction. As varieties, particularly, the Coratina species are particularly preferably used because of their high acteoside content.

  The wrinkle formation inhibitor containing the acteoside of the present invention as an active ingredient is, in particular, vegetation water obtained by squeezing olive fruit, or a solid phase part and / or an aqueous phase part obtained by squeezing olive fruit. Is preferably used. Vegitation water obtained by squeezing olive fruits is an aqueous solution part produced in the squeezing process of obtaining olive oil from ordinary olive fruits. Moreover, the solid phase part obtained by squeezing olive fruit and / or the solid phase part in the aqueous phase part is a precipitated part containing a pressed residue which is a solid content other than the liquid phase separated in the compressed product of olive fruit. And a liquid phase is also included as part of it. The aqueous phase portion is the remaining portion after removing the oil phase, which is olive oil, from the liquid phase portion through a process such as centrifugation.

  These vegetation water, or the solid phase part and / or the aqueous phase part can be used as they are, but usually by filtering or centrifuging the lipid component, fiber component, seed shell, etc. to be mixed. It is preferable to use after removing and purifying. In addition, for the purpose of suppressing the generation of off-flavors due to contamination with germs, it is possible to perform filtration or centrifugation after adding alcohols to the vegetation water or the solid phase and / or the aqueous phase. Examples of the alcohols used here include hydrophilic alcohols such as ethyl alcohol, isopropyl alcohol, 1,3-butylene glycol, and propylene glycol, and polyhydric alcohols. The total amount is preferably 5 to 80% by mass, It is particularly preferable to add so that the amount is 10 to 40% by mass.

  Furthermore, in the present invention, in order to efficiently recover the active ingredient acteoside, extraction is performed using water and / or an organic solvent from the solid phase part and / or the aqueous phase part obtained by pressing olive fruit. It is preferable to use the extract. Examples of the water and / or organic solvent used include water, hydrophilic alcohols such as ethyl alcohol, isopropyl alcohol, 1,3-butylene glycol, and propylene glycol, polyhydric alcohols, and mixtures thereof.

  The above-mentioned vegetation water, the solid phase part and / or the aqueous phase part, and the extract can be used after being concentrated, dried or solidified, if necessary. Furthermore, in order to increase the content of acteoside in these, it is also possible to purify by various known purification means. The content of acteoside which is an active ingredient of the wrinkle formation inhibitor of the present invention is preferably 1.0% by mass or more based on the wrinkle formation inhibitor. When the content of acteoside is 1.0% by mass or more, the wrinkle formation inhibitory effect of the present invention is sufficiently exerted, and the wrinkle formation inhibitor is used as a functional ingredient in various cosmetics and food and beverage compositions. At this time, it becomes possible to ensure a sufficient degree of freedom in blending.

  The wrinkle formation inhibitor of the present invention can be imparted with a wrinkle formation inhibitory function to these cosmetics by being blended as a functional ingredient in various general cosmetics. As cosmetics, in addition to cosmetics generally applied to the skin, they may be used as bathing agents. As the dosage form, it is possible to use a commonly used aqueous solution, W / O type or O / W type emulsion, appropriate excipients, etc. to form granules or other powders, tablets, etc., specifically Examples include, but are not limited to, creams, emulsions, lotions, packs, gels, sticks, sheets, and pops. The blending amount of the wrinkle formation inhibitor with respect to the cosmetics should be appropriately selected according to the dosage form and cannot be specified unconditionally. However, in general, the wrinkle formation inhibitor of the present invention is used with respect to the total amount of the cosmetics. The acteoside, which is the active ingredient, is preferably blended in an amount of 0.001 to 2.0% by mass, particularly preferably 0.001 to 1.0% by mass. If the blending amount is less than 0.001% by mass, the effect of suppressing the formation of wrinkles may not be sufficiently obtained, and if it exceeds 2.0% by mass, the improvement corresponding to the increase may not be expected. The problem that the sensory sensation at the time of use deteriorates, particularly the problem that the smell becomes too strong is likely to occur, and it may be difficult to maintain individual dosage forms.

  When applying the wrinkle formation inhibitor of the present invention to cosmetics, various components that are generally applicable to cosmetics, such as tar dyes, oxidation, and the like, as long as they do not impair the effects of the present invention. Color pigments such as iron, preservatives such as parabens, fatty acid soaps, anionic surfactants such as sodium cetyl sulfate, polyoxyethylene alkyl ethers, polyoxyethylene fatty acid esters, polyoxyethylene polyhydric alcohol fatty acid esters, polyoxy Nonionic surfactants such as ethylene hydrogenated castor oil, polyhydric alcohol fatty acid ester, polyglycerin fatty acid ester, cationic surfactants such as tetraalkylammonium salt, betaine type, sulfobetaine type, sulfoamino acid type, N- Zwitterionic surfactants such as stearoyl-L-glutamate sodium, , Natural surfactants such as lysophosphatidylcholine, gelatin, casein, starch, gum arabic, karaya gum, guar gum, locust bean gum, dragacanto gum, quince seed, pectin, carrageenan, sodium alginate, methylcellulose , Semi-synthetic polymers such as hydroxyethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose, synthetic polymers such as polyvinyl alcohol, polyvinyl methyl ether and copolymer, polyvinyl pyrrolidone, sodium polyacrylate, carboxyvinyl polymer, polyethylene oxide polymer , Thickeners such as xanthene gum, pigments such as titanium oxide, antioxidants such as dibutylhydroxytoluene, etc. That.

  Moreover, the wrinkle formation inhibitor of this invention can provide a wrinkle formation inhibitory function to these food / beverage products compositions by mix | blending as a functional component with various general food / beverage products compositions. The food / beverage composition can be in any dosage form suitable for oral intake, and examples thereof include tablets, granules, various capsules, drink preparations, solid preparations and the like. Examples of the food and drink include, but are not limited to, beverages, jelly, chewing gum, candy, and tablet confectionery. The blending amount of the wrinkle formation inhibitor with respect to the food / beverage composition should be appropriately selected depending on the dosage form and cannot be specified unconditionally. The agent is preferably blended so as to be 0.001 to 10.0% by mass, particularly preferably 0.001 to 5.0% by mass, as the active ingredient, acteoside. If the blending amount is less than 0.001% by mass, it is substantially difficult to ingest acteoside necessary for exerting the effect of suppressing wrinkle formation. Moreover, even if it exceeds 10.0 mass%, the effect commensurate with it is not necessarily acquired, and when an excessive intake of the food / beverage product composition is more than necessary, there is a possibility of having an unfavorable effect on health.

  When applying the wrinkle formation inhibitor of the present invention to a food / beverage product composition, various active ingredients generally applicable to food / beverage products, such as vitamin C, as long as they do not impair the effects of the present invention. Vitamins such as Vitamin E, Vitamin B2, Vitamin B6, Nicotinamide, Minerals such as Magnesium, Zinc, Chromium, Banaba, Gymnema, Aloe, Lacanca, Macomo, Mulberry Leaves, Loquat Leaves, Cargo Leaves, Salacia, Red It is more effective to add geiten, indigestible dextrin, stone lotus, tea polyphenol, theanine, histidine, ginseng, seaweed, hops, caiapoimo, brewer's yeast and the like. Moreover, an emulsifier, a dispersing agent, a suspending agent, a spreading agent, a penetrating agent, a wetting agent, a stabilizer and the like can be combined.

  The wrinkle formation inhibitor of the present invention can effectively exert the wrinkle formation inhibitory effect, which is its purpose, by ingesting an appropriate amount orally on a daily basis. As a preferred method of ingesting wrinkle formation inhibitors, it is divided into 1 to 3 times so that it is 0.001 to 0.05 g, particularly preferably 0.001 to 0.01 g as acteoside per day for adults. A method is mentioned. If the daily intake is less than 0.001 g, the wrinkle formation inhibitory effect may be insufficient, and even if it exceeds 0.05 g, an effect commensurate with it may not be obtained.

  EXAMPLES Hereinafter, although this invention is explained in full detail based on an Example, this invention is not necessarily limited to these Examples.

Example 1 (Production of Acteoside Crude Product)
2 kg of colatina olive fruit was squeezed, and a solid phase part and an aqueous phase part were recovered according to a conventional method. Hydrous ethanol was added to the recovered solid phase part and aqueous phase part and extracted twice. The obtained extract was concentrated and dried by a conventional method to obtain an “acteoside crude product” having an acteoside content of 5.0% by mass.

Example 2 (Production of purified acteoside product)
250 g of crude acteoside product obtained in Example 1 was extracted with methanol, and the solvent was removed from the extract under reduced pressure to obtain 210 g of a methanol extract. Next, 14.4 L of an aqueous solution in which the methanol extract was re-dissolved in purified water was passed through a column packed with a styrene synthetic adsorbent (Amberlite XAD1180, manufactured by Organo Corporation), washed with purified water, Elution was carried out sequentially using an aqueous methanol solution whose concentration was changed stepwise. After removing the solvent under reduced pressure from the fraction eluted with 50% by mass methanol aqueous solution, the solution was freeze-dried to obtain an “acteoside purified product” having an acteoside content of 34.0% by mass.

Examples 3 and 4, Comparative Example 1 (wrinkle formation suppression test by external application)
The effect of suppressing wrinkle formation by external application of acteoside, which is an active ingredient of the wrinkle formation inhibitor of the present invention, was examined by a test using the following photoaging model.

(Test method)
1. Test animals One group of 8 hairless mice aged 10 weeks at the start of the test was used.

2. 2. Wrinkle formation inhibition test 2-1. Photoaging conditions Photoaging was induced by irradiating the back of hairless mice with UVA and UVB, once a day, 5 times a week for 4 consecutive weeks. Irradiation dose, UVA has a ^{20J / cm 2, 25J / cm} 2, 30J / cm 2, UVB is ^{20mJ / cm 2, 30mJ / cm} 2, 40mJ / cm 2, escalated the dose every week And after the 3rd week, it irradiated with each maximum irradiation amount.

2-2. Evaluation method The wrinkle suppression effect was evaluated by changes in the dermis collagen content and skin thickness.
Dermal collagen amount: The whole skin is collected and crushed with a Polytron homogenizer (KINEMATICA), then the collagen fraction is extracted and acid hydrolyzed, and the hydroxyproline content is determined using an amino acid analyzer (manufactured by JASCO). And quantified. The amount of hydroxyproline per cm ² was used as a relative index of dermis collagen content.
Epidermis thickness: The skin of all layers was collected and a skin section sample was prepared according to a conventional method, followed by hematoxylin and eosin staining, and the thickness of the epidermis was measured with image analysis software (Microanalyzer, manufactured by Pola Digital Japan).

2-3. Sample and Test Procedure Using 50% by mass ethanol aqueous solution as a base (Comparative Example 1), a sample containing 0.5% by mass of Acteoside (manufactured by ChromaDex) and a sample containing 10% by mass of Acteoside crude purified product of Example 1 Was prepared and applied to test animals (Examples 3 and 4). Application was performed at the same frequency as UV irradiation, and once UV irradiation was completed once a day, 0.1 mL of the sample was applied to the back skin of hairless mice (diameter: about 2.5 cm). After finishing the final application, the skin was collected by slaughter, and the dermis collagen content (hydroxyproline amount per 1 cm ² ) and epidermis thickness were measured, and the difference was compared using the base application group of Comparative Example 1 as a control. .

(result)
Tables 1 and 2 show the results of evaluating the effect of the wrinkle formation inhibitor of the present invention on ultraviolet ray-induced wrinkle formation in mice using the dermis collagen content and skin thickness, which have an important role in wrinkle formation, as indices.

[Table 1] (Dermal collagen content)
――――――――――――――――――――――――――――――――
Sample concentration Concentration of hydroxyproline ^a)
(Mass%) (μmol / cm ² )
――――――――――――――――――――――――――――――――
Example 3 Acteoside 0.5 4.98 ± 0.35 ^b)
Example 4 Acteoside Crude Product 10.0 4.96 ± 0.34 ^b)
Comparative Example 1-(Base only)-3.85 ± 0.44
――――――――――――――――――――――――――――――――
a) Values are mean values ± standard error, b) p <0.05 (significant difference from Comparative Example 1)

  The actineoside and acteoside crude product application groups of Examples 3 and 4 showed significantly higher collagen content (hydroxyproline amount) than that of Comparative Example 1 with only the base, and the amount of dermal collagen decreased by photoaging. In contrast, acteoside was shown to be effective.

[Table 2] (Skin thickness)
―――――――――――――――――――――――――――――――――
Test sample concentration Skin thickness ^c)
(Mass%) (μm)
―――――――――――――――――――――――――――――――――
Example 3 Acteoside 0.5 45.02 ± 1.56 ^d)
Example 4 Acteoside Crude Product 10.0 46.03 ± 1.66 ^d)
Comparative Example 1-(Base only)-55.27 ± 2.52
―――――――――――――――――――――――――――――――――
c) Numerical values are mean ± standard error, d) p <0.01 (significant difference from Comparative Example 1)

  In the groups of Acteoside and Acteoside crude product application of Examples 3 and 4, the value of the skin thickness is significantly lower than that of Comparative Example 1 with only the base, and the Acteoside has a thickness that is thickened by photoaging. It was shown to be effective.

  From the results of this test, Acteoside clearly has an effect of suppressing wrinkle formation because it significantly increases the amount of collagen decreased by photoaging and also suppresses thickening of the epidermis. It was thought to be.

Examples 5 and 6, Comparative Example 2 (oral wrinkle formation inhibition test)
The oral wrinkle formation inhibitory effect of acteoside, which is an active ingredient of the wrinkle formation inhibitor of the present invention, was examined by a test using the following photoaging model.

(Test method)
1. Test animals One group of 9 hairless mice 10 weeks of age at the start of the test was used.

2. 2. Wrinkle formation inhibition test 2-1. Photoaging conditions and evaluation method Photoaging was induced by UV irradiation under the same conditions as in the “wrinkle formation inhibition test by external application” described above. However, the irradiation period was 12 weeks. The wrinkle suppression effect was evaluated by the wrinkle score. The wrinkle score was scored according to the method of Bissett et al. (Photochem. Photobiol., 46: 367-378, 1987). That is, with the naked eye judgment that combines the size and depth of the wrinkles, the highest point is 3 points, 3 points can be observed for large and deep wrinkles, 2 points can be confirmed for wrinkles, and wrinkles cannot be confirmed. Was scored as 1 point, and “normal texture can be observed” as 0 point.

2-2. Sample and test procedure As test sample, Acteoside (manufactured by ChromaDex), Acteoside purified product of Example 2 was used, 0.5% by mass carboxymethylcellulose aqueous solution was used as a base (Comparative Example 2), and the test sample was dispersed in the base And administered to test animals (Examples 5 and 6). The administration was started from the 5th week after the start of UV irradiation, and the sample was administered directly into the stomach with a sonde so that the dose shown in Table 3 was given to each test animal before the start of UV irradiation on each irradiation day. The concentration of each test sample was adjusted as appropriate so that the administration volume in each group was the same. And the wrinkle score was scored 3 days after the end of the final irradiation, and the difference was compared using the base administration group of Comparative Example 2 as a control.

(result)
Table 3 shows the results of evaluating the effect of the wrinkle formation inhibitor of the present invention on UV-induced wrinkle formation in mice using the wrinkle score as an index.

[Table 3] (wrinkle score)
―――――――――――――――――――――――――――――――――
Test sample Dose wrinkle score ^e)
(Mg / kg)
―――――――――――――――――――――――――――――――――
Example 5 Acteoside 2.10 1.80 ± 0.30
8.50 1.50 ± 0.25 ^f)
Example 6 Acteoside purified product 6.25 1.75 ± 0.32
25.0 1.60 ± 0.28 ^f)
Comparative Example 2-(Base only)-2.65 ± 0.18
―――――――――――――――――――――――――――――――――
e) Numerical values are mean ± standard error, f) p <0.05 (significant difference from Comparative Example 2)

  The low dose administration group of acteoside and acteoside purified product in Examples 5 and 6 was found to have a tendency to suppress wrinkle formation induced by ultraviolet irradiation as compared with the base administration group of Comparative Example 2. Furthermore, it was found that both the wrinkle formations were significantly suppressed in the high dose administration group.

  In this test, weight loss due to failure of oral administration or the like was not observed, and a normal growth curve was obtained. Therefore, it became clear that this test result was not simply due to poor physical condition.

  The wrinkle formation inhibitor of the present invention can be provided as various preparations as shown in the following examples, but is not limited thereto. In addition,% of a compounding quantity is all the mass%.

Example 7 (skin lotion)
After the B component was uniformly dissolved in the C component, the A component and the C component were mixed and stirred and dispersed uniformly, and then filled into a container to prepare a skin lotion.
Compounding ingredients Compounding amount (%)
-----------------------
(A)
Ethanol 10.0
Monolauric acid 5.0
Polyoxyethylene (20) sorbitan dibutylhydroxytoluene 0.01
Fragrance 0.05
(B)
Acteoside crude product of Example 1 0.5
(C)
Glycerin 5.0
Xanthan gum 0.1
Hydroxyethyl cellulose 0.1
Purified water balance

Example 8 (skin cream)
The mixture of component A and component B is heated and dissolved uniformly to bring the temperature to 80 ° C. Next, component C was injected and emulsified therein, and then cooled to 30 ° C. with stirring to prepare a skin cream.
Compounding ingredients Compounding amount (%)
-----------------------
(A)
Glycerol monostearate 2.0
Honey wax 1.0
Monooleic acid 6.0
Polyoxyethylene (20) sorbitan petrolatum 4.0
Liquid paraffin 12.0
(B)
Acteoside crude product of Example 1 0.5
(C)
N-stearoyl 1.0
-Sodium L-glutamate carrageenan 0.3
Methylparaben 0.1
Purified water balance

Example 9 (tablet)
The following components were uniformly mixed, and tablets were prepared by a conventional method.
Compounding ingredients Compounding amount (%)
-----------------------
Acteoside (ChromaDex) 0.15
Reduced malt syrup 49.0
Crystalline cellulose 43.85
Agar powder 4.0
Fragrance 1.0
Sucrose fatty acid ester 2.0

Example 10 (granule)
The following components were uniformly ground and mixed, and granules were prepared by a conventional method.
Compounding ingredients Compounding amount (%)
-----------------------
Acteoside purified product of Example 2 1.0
Starch 40.0
Lactose 58.0
Crystalline cellulose 1.0

Example 11 (soft capsule)
The following components were mixed, filled into a gelatin film composed of gelatin and glycerin, and made into a soft capsule by a conventional method.
Compounding ingredients Compounding amount (%)
-----------------------
Acteoside purified product of Example 2 3.0
Soybean oil 52.0
Vitamin E 20.0
Wheat germ oil 15.0
Glycerin fatty acid ester 5.0
Beeswax 5.0

Example 12 (hard capsule)
The following components were mixed and filled into a capsule container made of gelatin to obtain a hard capsule by a conventional method.
Compounding ingredients Compounding amount (%)
-----------------------
Acteoside purified product of Example 2 5.0
Reduced malt syrup 60.0
Dextrin 34.0
Glycerin fatty acid ester 1.0

Example 13 (drink agent)
The following components were mixed and used as a drink by a conventional method.
Compounding ingredients Compounding amount (%)
-----------------------
Acteoside (ChromaDex) 0.004
Reduced malt syrup 20.0
Erythritol 10.0
Citric acid 1.0
Purified water balance

Example 14 (jelly preparation)
The following components were mixed and made into a jelly preparation by a conventional method.
Compounding ingredients Compounding amount (%)
-----------------------
Acteoside purified product of Example 2 0.04
Dextrin 24.0
Palatinose 5.0
Gelatin 1.0
Pectin 0.5
Inositol 5.0
Citric acid 0.8
Ascorbic acid 3.0
Nicotinamide 0.01
Purified water balance

Example 15 (chewing gum)
The following components were mixed and a chewing gum was prepared by a conventional method.
Compounding ingredients Compounding amount (%)
-----------------------
Acteoside crude product of Example 1 1.0
Gum base 25.0
Maltitol 45.0
Mannit 20.0
Sorbitol 5.0
Fragrance 1.0
Purified water balance

Example 16 (Gummy Candy)
The following components were mixed and gummy candy was prepared by a conventional method.
Compounding ingredients Compounding amount (%)
-----------------------
Acteoside crude product of Example 1 1.0
Granulated sugar 34.0
Minamata 30.0
Gelatin 10.0
Citric acid 0.5
Tartaric acid 0.3
Fragrance 1.0
Purified water balance

The wrinkle formation inhibitor of the present invention has an excellent wrinkle formation inhibitory action when applied externally and / or taken orally, and is an aqueous solution, W / O type or O / W type emulsion, tablet, granule, various capsules , Drink preparations, solid preparations, etc. Cosmetics can be creams, emulsions, lotions, packs, gels, sticks, sheets, and papps. Moreover, as food and drink, it can be set as a drink, jelly, chewing gum, a candy, a tablet confectionery, etc., and it is useful for the use aiming at wrinkle formation suppression.

Claims (7)

A wrinkle formation inhibitor comprising acteoside represented by the following formula as an active ingredient.

The wrinkle formation inhibitor is a vegetation water obtained by squeezing olive fruit, or a solid phase part and / or an aqueous phase part obtained by squeezing olive fruit. Wrinkle formation inhibitor. The wrinkle formation inhibitor is an extract obtained by extracting water and / or an organic solvent from a solid phase part and / or an aqueous phase part obtained by pressing olive fruit. 1. The wrinkle formation inhibitor according to 1. The wrinkle formation inhibitor according to any one of claims 1 to 3, wherein the content of acteoside in the wrinkle formation inhibitor is 1.0% by mass or more. It is cosmetics which mix | blend the wrinkle formation inhibitor of any one of Claims 1-4, and the compounding quantity of the acteoside which is an active ingredient of the said wrinkle formation inhibitor is the total amount of cosmetics. A wrinkle formation-inhibiting cosmetic, characterized in that the content is 0.001 to 2.0% by mass. It is a food / beverage composition characterized by mix | blending the wrinkle formation inhibitor of any one of Claims 1-4, and the compounding quantity of the acteoside which is an active ingredient of the said wrinkle formation inhibitor is food / beverage products. The food / beverage composition for wrinkle formation suppression characterized by being 0.001-10.0 mass% on the basis of the total amount of a composition. An ingestion method comprising orally administering 0.001 g to 0.05 g of acteoside, which is an active ingredient of the wrinkle formation inhibitor according to any one of claims 1 to 4, per day.